Symbols

IPSC

Century Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 3

Stock Price Surged Significantly

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Gap Up

Significant Revenue Decline

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IPSC

Century Therapeutics, Inc.

An innovative biotech company that develops induced pluripotent stem cell -derived cell therapies in immuno-oncology

Industry

Biological Technology

Established Date

03/05/2018

Listing Date

06/18/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.centurytx.com

Security Type

Common stock

Office address

25 N 38th Street, 11th Floor, Philadelphia, Pennsylvania 19104

Business

Introduction

Century Therapeutics, Inc., was incorporated in Delaware on March 5, 2018. The company is a biotechnology company focused on the development of allogeneic pluripotent stem cell therapies for autoimmune diseases and cancer. Its platform utilizes induced pluripotent stem cells to generate a variety of cell types, including islet beta cells and immune cells, and is engineered with proprietary technology to prevent host immune rejection.

Company Financials

EPS

IPSC has released its 2025 Q4 earnings. EPS was reported at -0.25, versus the expected -0.3, beating expectations. The chart below visualizes how IPSC has performed over recent quarters, highlighting trends in earnings surprises.